Anaesthetics and the rate corrected interval: Learning from droperidol?

Current Opinion in Anaesthesiology

Volumn 18, Issue 4, 2005, Pages 419-423

  Shipton, Edward A ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Acquired long QT syndrome; Anaesthetic drugs; Congenital long QT syndrome; Droperidol; Pathophysiology; Preclinical tests; Treatment

Indexed keywords

ALFENTANIL; ANESTHETIC AGENT; ATROPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DESFLURANE; DROPERIDOL; ESMOLOL; ETOMIDATE; GLYCOPYRRONIUM BROMIDE; HALOTHANE; ION CHANNEL; ISOFLURANE; ISOPRENALINE; KETAMINE; MAGNESIUM SULFATE; METHADONE; METHOHEXITAL; MIDAZOLAM; NEOSTIGMINE; OPIATE; POTASSIUM CHANNEL STIMULATING AGENT; PROPOFOL; PROTEIN KINASE INHIBITOR; REMIFENTANIL; SEVOFLURANE; SODIUM CHANNEL BLOCKING AGENT; SUXAMETHONIUM; THIOPENTAL;

DIAGNOSTIC TEST; DNA SCREENING; DRUG SAFETY; GENETIC SUSCEPTIBILITY; GENOTYPE; HEART ARRHYTHMIA; HEART DEPOLARIZATION; HEART PACING; HEART VENTRICLE ARRHYTHMIA; HOMEOSTASIS; HUMAN; INTRAOPERATIVE PERIOD; LONG QT SYNDROME; MOLECULAR GENETICS; NONHUMAN; PERIOPERATIVE PERIOD; POTASSIUM CURRENT; PRIORITY JOURNAL; QT DISPERSION; QT INTERVAL; QT PROLONGATION; REPOLARIZATION; REVIEW; RISK FACTOR; SYMPATHECTOMY; TORSADE DES POINTES;

EID: 23044454560     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aco.0000168329.10067.1a     Document Type: Review

References (32)

1. Richards JR, Schneir AB. Droperidol in the emergency department: is it safe? J Emerg Med 2003; 24:441-447.
2. Zhang Y, Luo Z, White PF. A model for evaluating droperidol's effect on the median QTc interval. Anesth Analg 2004; 98:1330-1335. The authors make use of a mathematical model to evaluate the relationship between the dose of droperidol and QT(c) prolongation.
3. Kornick CA, Kilborn MJ, Santiago-Raima J, et al. QTc interval prolongation associated with intravenous methadone. Pain 2003; 105:499-506.
4. Kao LW, Kirk MA, Evers SJ, Rosenfeld SH. Droperidol, QT prolongation, and sudden death: what is the evidence? Ann Emerg Med 2003; 41:546-558.
5. Khan IA, Gowda RM. Novel therapeutics for treatment of long-QT syndrome and torsade de pointes. Int J Cardiol 2004; 95:1-6. The authors speculate on future therapeutic strategies for the treatment of LQTS and TdP. These include sodium antagonists, potassium channel activators and protein kinase inhibitors.
6. Mancuso EM, Brady WJ, Harrigan RA, et al. Electrocardiographic manifestations: long QT syndrome. J Emerg Med 2004; 27:385-393. The authors describe the epidemiology and pathophysiology, the clinical presentation, the electrocardiographic manifestations, the diagnosis and management of LQTS.
7. TO,f), are not a frequent cause of long QT syndrome. Clin Chim Acta 2005; 351:95-100.
8. Booker PD, Whyte SD, Ladusans EJ. Long QT syndrome and anaesthesia. Br J Anaesth 2003; 90:349-366.
9. Chiang CE. Congenital and acquired long QT syndrome. Current concepts and management. Cardiol Rev 2004; 12:222-234. The author reviews the current concepts and management of congenital and acquired LQTS.
10. Ackerman MJ. Molecular basis of congenital and acquired long QT syndromes. J Electrocardiol 2004; 37(Suppl. 1):1-6. The author discusses the molecular basis of congenital and acquired LQTS. The different phenotypes are detailed, and the medical conditions and drugs associated with acquired LQTS mentioned.
11. Gong Q, Keeney DR, Robinson JC, Zhou Z. Defective assembly and trafficking of mutant HERG channels with C-terminal truncations in long QT syndrome. J Mol Cell Biol 2004; 37:1225-1233.
12. Gowda RM, Khan IA, Wilbur SL, et al. Torsade de pointes: the clinical considerations. Int J Cardiol 2004; 96:1-6. The authors explore the electrophysiological mechanisms of LQTS and the development of TdP.
13. Chiba K, Sugiyama A, Takasuna K, Hashimoto K. Comparison of sensitivity of surrogate markers of drug-induced torsades de pointes in canine hearts. Eur J Pharmacol 2004; 502:117-122.
14. Shah RR. Drug-induced QT interval prolongation: regulatory perspectives and drug development. Ann Med 2004; 36(Suppl. 1):47-52.
15. Joshi A, Dimino T, Vohra Y, et al. Preclinical strategies to assess QT liability and torsadogenic potential of new drugs: the role of experimental models. J Electrocardiol 2004; 37(Suppl. 1):7-14. The authors discuss the preclinical strategies designed to assess the QT liability and torsadogenic potential of new drugs. Of special importance is the use of the rabbit left ventricle wedge preparation that exhibits high sensitivity and specificity for the identification of compounds positive and negative for QT prolongation and TdP.
16. Satoh Y, Sugiyama A, Takahara A, et al. Electropharmacological and proarrhythmic effects of a class III antiarrhythmic drug nifekalant hydrochloride assessed using the in vivo canine models. J Cardiovasc Pharmacol 2004; 43:715-723.
17. Wisely NA, Shipton EA. Long QT syndrome and anaesthesia. Eur J Anaesthesiol 2002; 19:853-859.
18. Hoshino K, Ogawa K, Hishitani T, et al. Optimal administration dosage of magnesium sulfate for torsades de pointes in children with long QT syndrome. J Am Coll Nutr 2004; 23:4975-5008.
19. Katz RI, Quijano I, Barcelon N, Biancaniello T. Ventricular tachycardia during general anesthesia in a patient with congenital long QT syndrome. Can J Anaesth 2003; 50:398-403.
20. Kleinsasser A, Loeckinger A, Lindner KH, et al. Reversing sevoflurane-associated Q-Tc prolongation by changing to propofol. Anaesthesia 2001; 56:248-250.
21. Ay B, Fak AS, Toprak A, et al. QT dispersion increases during intubation in patients with coronary artery disease. J Electrocardiol 2003; 36:99-104.
22. Tanskanen PE, Kytta JV, Randell TT. QT interval and QT dispersion during the induction of anaesthesia in patients with subarachnoid haemorrhage: a comparison of thiopental and propofol. Eur J Anaesthesiol 2002; 19:749-754.
23. Yildirim H, Adanir T, Atay A, et al. The effects of sevoflurane, isoflurane and desflurane on QT interval of the ECG. Eur J Anaesthesiol 2004; 21:566-570.
24. Sen S, Ozmert G, Boran N, et al. Comparison of single-breath vital capacity rapid inhalation with sevoflurane 5% and propofol induction on QT interval and haemodynamics for laparoscopic surgery. Eur J Anaesthesiol 2004; 21:543-546.
25. Yamada M, Hatakeyama N, Shibuya N, et al. Mechanism of QT interval prolongation induced by sevoflurane in guinea-pig ventricular myocyte. Masui 2O03; 52:482-488.
26. Loeckinger A, Kleinsasser A, Maier S, et al. Sustained prolongation of the QTc interval after anesthesia with sevoflurane in infants during the first 6 months of life. Anesthesiology 2003; 98:639-642.
27. Gil M, Sala M, Anguera I, et al. QT prolongation and torsades de pointes in patients infected with human immunodeficiency virus and treated with methadone. Am J Cardiol 2003; 92:995-997.
28. Milberg P, Reinsch N, Wasmer K, et al. Transmural dispersion of repolarization as a key factor of arrhythmogenicity in a novel intact heart model of LQT3. Cardiovasc Res 2005; 65:397-404.
29. Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA 2004; 292:1341-1344.
30. Koren G. Electrical remodeling and arrhythmias in long-QT syndrome: lessons from genetic models in mice. Ann Med 2004; 36(Suppl. 1):22-27.
31. van Langen IM, Hofman N, Tan HL, Wilde AA. Family and population strategies for screening and counselling of inherited cardiac arrhythmias. Ann Med 2004; 36(Suppl. 1):116-124. The authors examine new strategies for screening and for the counselling of inherited cardiac arrhythmias.
32. Luo S, Michler K, Johnston P, Macfarlane PW. A comparison of commonly used QT correction formulae: the effect of heart rate on the QTc of normal ECGs. J Electrocardiol 2004; 37(Suppl. I):81 -90. The authors compare four commonly used QT correction formulae and recommend the Hodges formula be used to replace the popular Bazett's formula for QTc correction.